Understand the source comparison
5-Amino-1MQ vs Tesofensine: Research Comparison
Mechanism of Action NNMT enzyme inhibition restoring NAD+ biosynthesis and mitochondrial function Triple monoamine reuptake inhibition (SERT, NET, DAT) extending synaptic neurotransmitter presence Fundamentally distinct pathways. One metabolic enzyme modulatio
No winner is assigned.
This page preserves a source comparison for education. It does not add a rating, recommendation or clinical judgment.
- Mechanism of Action
- NNMT enzyme inhibition restoring NAD+ biosynthesis and mitochondrial function
- Triple monoamine reuptake inhibition (SERT, NET, DAT) extending synaptic neurotransmitter presence
- Fundamentally distinct pathways. One metabolic enzyme modulation, one CNS neurotransmitter modulation
- Primary Research Context
- NAD+ depletion, mitochondrial dysfunction, insulin resistance independent of appetite
- Appetite suppression, binge eating, caloric intake reduction through satiety enhancement
- 5-Amino-1MQ targets energy production efficiency; tesofensine targets intake behavior
- Human Clinical Data
- Minimal. No Phase 2 or Phase 3 trials published
- Phase 2 trials (The Lancet 2008) showing 12.8% weight reduction at 0.5mg over 24 weeks
- Tesofensine has established efficacy data; 5-Amino-1MQ evidence is preclinical
- Known Adverse Events
- Theoretical methylation disruption, mild flushing (anecdotal)
- Dry mouth (30–40%), nausea (20–25%), increased heart rate (+6–8 bpm), elevated BP
- Tesofensine's cardiovascular effects are documented and clinically significant
- FDA Approval Status
- Not approved. Research compound only
- Not approved. Phase 3 halted due to safety concerns
- Neither compound has regulatory approval for therapeutic use in 2026
- Typical Research Dose Range
- 50–150mg daily (rodent-equivalent dosing, human extrapolation unclear)
- 0.25–1.0mg daily (human trial dosing)
- Dose comparability is not meaningful due to different mechanisms